about
Comparison of FDG PET and SPECT for detection of bone metastases in breast cancerBrain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases.Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.Can T2-weighted 3-T breast MRI predict clinically occult inflammatory breast cancer before pathological examination? A single-center experience.Real-time virtual sonography examination and biopsy for suspicious breast lesions identified on MRI alone.Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells.HTLV-I carrier status disclosed at diagnosis of cytomegalovirus gastric ulcer.Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3 T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.Should breast MRI be performed with adjustment for the phase in patients' menstrual cycle? Correlation between mammographic density, age, and background enhancement on breast MRI without adjusting for the phase in patients' menstrual cycle.Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent.Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer?[Leptomeningeal Dissemination in Patients with Pituitary Metastasis from Breast Cancer].Trigeminal neuralgia caused by lymphomatous compression at oval foramenClip placement after an 11-gauge vacuum-assisted stereotactic breast biopsy: correlation between breast thickness and clip movementMetastatic breast carcinoma of the abdominal wall muscle: a case reportIs lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in JapanImpact of race on dose selection of molecular-targeted agents in early-phase oncology trialsIs the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE studyA multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patientsA maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experienceHepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic ChemotherapiesMRI-detected breast lesions: clinical implications and evaluation based on MRI/ultrasonography fusion technologyReply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer
P50
Q28241534-196D9D29-634D-4006-9C72-1457783D24BEQ31154571-CB054B49-C955-45B9-A078-E782857B285EQ33402421-307D6FEC-32FF-4FD7-B906-327F1FF5FF34Q33441316-A7123858-4B62-4C5B-A306-7B7D9021FC8FQ33738990-C3BB0F87-C99D-48A0-B8AF-5C789DEA4505Q36067578-6E6CEF43-EF05-4BCB-9D59-1C5BB4E4A321Q36234055-BD84BD91-1AA0-475F-8CF3-6F8185A4D027Q36470125-03332C79-6EF4-49F9-802A-42BF799ADACBQ37424096-81E5FC01-85DF-4697-BA82-EDE9A2690641Q38056072-B9AD6844-521B-4DF2-9F34-9D46F5AB8CBBQ38541885-5644F8DF-DB9B-4983-A1AE-F641867DA18BQ40339177-6D92C442-8AE7-4ED8-ABE5-95077B2A7D8EQ40399023-385F8389-0299-4A23-86AF-13D324592522Q40721004-77A70A1C-468F-4D4C-9A77-8B02CDC03A01Q44281614-290FB73F-8118-4CB5-A204-DF5577F266AAQ44803594-6606454A-2C48-4BC7-AD4A-2B1E34B5C073Q44969452-5E0893D0-BA0D-465D-A336-3AEB6E48FFD8Q45802901-DE7F3CCE-4773-4BC5-964B-DD8C4C995986Q47999034-2CDD2911-72B3-41B7-8951-39F1E8857ADCQ48157533-4E99B3B3-45F7-46AE-907D-6B070BE2437BQ53084701-285EDF60-01F7-4CC7-9051-C68732251650Q53085673-D7237E03-4A76-41D2-BD36-DD4CF9FCA7CAQ53103573-6F52834A-EC30-4617-9B2D-77C9C882EBF4Q74528529-138B05A6-6E76-465E-BBF8-FDD9C43679BAQ83316009-182E29C5-441A-4E53-A0A0-511B4A70550FQ83553952-5F972D87-2596-4FBC-9DB2-08F46BCF36A5Q84468915-6E4FE3D3-F7A8-41F7-BAF7-D1F5B387499FQ86499956-03965D0A-24AE-438F-8006-95CE16781E27Q88796639-10CE4309-2C63-4FDF-8826-F3BFDF2B2B91Q89731501-B8A0DE8D-7A1E-425C-BE35-14C345385B65Q90058373-4B6498D6-FD1C-40F4-9CF4-4EA91CF43A40Q91468473-9C3191C7-3FD5-478E-B578-EF02F1E36271Q91580178-A73552B9-27A8-4867-8716-9C92102D377BQ92286672-911BF010-7F78-4869-9134-A6CB36FFBA36Q93120252-78D30CE2-C941-42E7-AF30-50AB43926546Q95644570-4B83A8CE-1EA4-4410-9D90-80EA699EA349
P50
description
Japanese oncologist
@en
Japans oncoloog
@nl
oncólogo japonés
@es
oncólogu xaponés
@ast
name
Junichiro Watanabe
@ast
Junichiro Watanabe
@en
Junichiro Watanabe
@es
Junichiro Watanabe
@nl
type
label
Junichiro Watanabe
@ast
Junichiro Watanabe
@en
Junichiro Watanabe
@es
Junichiro Watanabe
@nl
prefLabel
Junichiro Watanabe
@ast
Junichiro Watanabe
@en
Junichiro Watanabe
@es
Junichiro Watanabe
@nl
P106
P2038
Junichiro_Watanabe
P21
P27
P31
P496
0000-0001-9226-895X